United Therapeutics

MD - Silver SpringBiotechnology3 H-1B visas (FY2023)

Focus: United Therapeutics is a specialty biotech company headquartered in Silver Spring, Maryland, focused on small molecules and biologics across cardiovascular, oncology, respiratory, nephrology, and infectious disease indications. The company is heavily concentrated on pulmonary hypertension therapies.

Cardiovascular Oncology Respiratory Nephrology

Profile data last refreshed 9h ago · AI intelligence enriched 2w ago

Open Jobs

About United Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow United Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

50 total

LOE Risk

2 in 5yr

REMODULIN

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

TYVASO DPI

Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease

$437M Part D

Peak

Help build intelligence for United Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

TYVASO DPI and TYVASO generate peak-stage revenues with patent protection extending to 2042, providing revenue stability for the next 18+ years
Diverse pipeline of 30 programs across rare disease (pulmonary hypertension, hemorrhagic fevers) and oncology with 3 Phase 3 programs offering near-term catalysts
Rare disease focus (pulmonary arterial hypertension specialist) enables deep clinical expertise and patient-centric culture rare in large pharma

Watch Out For

Extreme revenue concentration risk: 97% from a single drug formulation creates existential dependency on TYVASO DPI commercial performance and reimbursement stability
REMODULIN patent cliff approaching December 2028 with only $12M at risk, but early warning signal of portfolio vulnerability; limited diversification outside treprostinil franchise

Generated by Claude from United Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Flagship product representing 97% of company revenue with 18-year patent cliff protection.

TYVASO

Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease

Peak15.7yr

Original TYVASO formulation complementing DPI delivery; part of core treprostinil franchise.

REMODULIN

Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease

$12M Part D

LOE Approaching2.6yr

Subcutaneous formulation entering generic competition phase; early signal of portfolio erosion risk.

RENACIDIN

Catheter maintenance

$3M Part D

LOE Approaching

Minor nephrology product contributing negligibly to overall portfolio.

Pipeline & Clinical Trials

Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT01043627Sildenafil to Tadalafil in Pulmonary Arterial Hypertension (SITAR)

N/A

Adiposity and Iron Requirements in Pregnancy

Iron Deficiency Anemia of Pregnancy

N/A

Clinical Trials (1)

NCT06425796Adiposity and Iron Requirements in Pregnancy

N/A

Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT01799473Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

N/A

PET/MRI

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT04090866Cardiac Metabolic Remodeling After Pulmonary Vasodilator Therapy in Pulmonary Arterial Hypertension: A Pilot Study

N/A

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT01494896Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

N/A

SPRINT Peripheral Nerve Stimulation

Post-Amputation Pain

N/A

Model 10642 Implantable Intravascular Catheter

Pulmonary Arterial Hypertension

N/A

Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodul

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT02074449Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)

N/A

ChemoFX Assay

Breast Cancer

N/A

The Myelin Disorders Biorepository Project

Leukodystrophy

N/A

Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH

Pulmonary Arterial Hypertension

N/A

Remunity Pump for Remodulin

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT05060315Evaluate Real-World Use of Next Generation Infusion Pumps to Administer Remodulin

N/A

Prospective study assessments

Pulmonary Hypertension Due to Lung Diseases and Hypoxia

N/A

Clinical Trials (1)

NCT06388421DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

N/A

ACTIVE peripheral nerve stimulation with a percutaneously inserted lead and wearable stimulator

Rotator Cuff Repair

N/A

SPRINT Peripheral Nerve Stimulation

Low Back Pain

N/A

Remodulin

Congenital Heart Disease

N/A

ECG-based AI Device - Results Returned to Investigator

Pulmonary Hypertension

N/A

Treprostinil

Portopulmonary Hypertension

N/A

SPRINT Peripheral Nerve Stimulation

Postoperative Pain

N/A

Right heart catheterization

Interstitial Lung Disease

N/A

Clinical Trials (1)

NCT05776225Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection

N/A

Dinutuximab

Neuroblastoma

N/A

Clinical Trials (1)

NCT02693171Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

N/A

Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of TLD

HIV-1-infection

N/A

Oral treprostinil

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT03045029ADAPT - A Patient Registry of the Real-world Use of Orenitram®

N/A

inhaled prostacyclin

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT01266265Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

N/A

Treprostinil

Pulmonary Arterial Hypertension

N/A

Clinical Trials (1)

NCT03888365Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH

N/A

Data Collection

Hereditary Transthyretin Amyloidosis With Polyneuropthy

N/A

Clinical Trials (1)

NCT04850105A Non-interventional Cohort Safety Study of Patients With hATTR-PN

N/A

Exercise

Pulmonary Arterial Hypertension PAH

N/A

Clinical Trials (1)

NCT06477640Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension

N/A

Implantable System for Remodulin

Pulmonary Arterial Hypertension

N/A

SPR206

Renal Impairment

PHASE_1

UNEX-42

Bronchopulmonary Dysplasia

PHASE_1

Clinical Trials (1)

NCT03857841A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

Phase 1

Placebo

Alcohol Use Disorder (AUD)

PHASE_1

AVI-6003

Marburg Hemorrhagic Fever

PHASE_1

89Zr-DFO-YS5

Prostate Cancer

PHASE_1

Placebo

Ebola Hemorrhagic Fever

PHASE_1

ARN-75039 oral capsules

Lassa Virus Infection

PHASE_1

UT-15C

Healthy

PHASE_1

Clinical Trials (1)

NCT01746485Three Times Daily Dosing of UT-15C

Phase 1

oral treprostinil

Raynaud's Phenomenon

PHASE_1

Clinical Trials (1)

NCT02583789Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon

Phase 1

cNP8

Burns

PHASE_1

Treprostinil Inhalation Powder

Pulmonary Arterial Hypertension

PHASE_1

Clinical Trials (1)

NCT03950739Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso

Phase 1

Dexmedetomidine

Alcohol Use Disorder (AUD)

PHASE_1

CHR-2797

Advanced Solid Tumors

PHASE_1

Clinical Trials (1)

NCT00692354Safety Study to Evaluate CHR-2797 in Patients With Advanced Tumours

Phase 1

PNT001

Traumatic Brain Injury

PHASE_1

Clinical Trials (1)

NCT04677829Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

Phase 1

Glucagon

Type 1 Diabetes Mellitus With Hypoglycemia

PHASE_1

Clinical Trials (1)

NCT04712266A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes

Phase 1

UT-15C

Healthy

PHASE_1

Clinical Trials (1)

NCT02318758Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers

Phase 1

AVI-7288

Marburg Hemorrhagic Fever

PHASE_1

UKidney

Kidney Failure, Chronic

PHASE_1

Clinical Trials (1)

NCT05340426Porcine Kidney Xenotransplantation in Patients With End-Stage Kidney Disease

Phase 1

UT-15C SR

Pulmonary Arterial Hypertension

PHASE_1

Clinical Trials (1)

NCT01131845The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil

Phase 1

NDV-3 vaccine with alum IM

Staphylococcal Infections

PHASE_1

Clinical Trials (1)

NCT01447407Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine

Phase 1

ONX-0801

Solid Tumours

PHASE_1

Clinical Trials (1)

NCT02360345Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly

Phase 1

Inhaled treprostinil

Pulmonary Hypertension

PHASE_1

Clinical Trials (1)

NCT07116681Effects of Inhaled Treprostinil on Exercise Performance in Exercise Induced Pulmonary Hypertension

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 21 approved products, 116 clinical trials

Top TAs: Cardiovascular, Respiratory, Oncology

H-1B (2023): 3 approvals

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Portfolio Health

Launch1 (5%)

Peak5 (24%)

LOE Approaching4 (19%)

Post-LOE11 (52%)

21 total products

Therapeutic Area Focus

Cardiovascular

8 marketed70 pipeline

Respiratory

7 marketed22 pipeline

Oncology

2 marketed10 pipeline

Nephrology

1 marketed4 pipeline

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Visa Sponsorship

Sponsors Work Visas

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

INTRAVENOUS · INJECTABLE

Radiopharmaceutical Activity

3 marketed1 pipeline

Rare Diseases

1 marketed1 pipeline

Hematology

1 pipeline

United Therapeutics

About United Therapeutics

Why Work Here

Key Products

Watch Out For

Products & Portfolio (7)

Key Products by Revenue

Other Products (5)

Pipeline & Clinical Trials

Open Jobs (0)

Hiring Trend

Visa Sponsorship